Catia Martins1, Louise Kjelstrup, Ingrid L Mostad, Bård Kulseng. 1. Faculty of Medicine, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. catia.martins@ntnu.no
Abstract
BACKGROUND: Appetite-regulating hormones seem to play an important role in weight loss after bariatric surgery. Less is known regarding long-term weight loss maintenance. The objective of the study was to evaluate ghrelin and obestatin levels following long-term weight loss achieved through bariatric surgery or a lifestyle intervention in morbidly obese patients. METHODS: The study was cross-sectional in design carried out in a university research center setting. The participants were weight-stable morbidly obese patients who had undergone, on average, 3 years ago, Roux-en-Y gastric bypass (RYGB) surgery (n=9) or a lifestyle weight loss intervention (n=8), and patients on a waiting list for bariatric surgery (control group; n=9). The main outcome measures were fasting/postprandial plasma levels of total ghrelin and obestatin and ghrelin/obestatin ratio. RESULTS: Fasting ghrelin and obestatin plasma levels were significantly elevated in the RYGB, but not in the lifestyle group, as compared with the control group. There was no statistical significant difference in fasting ghrelin/obestatin ratio among study groups. Ghrelin levels were suppressed after breakfast in all groups, with no significant differences in postprandial levels overtime between them. Obestatin levels did not change postprandially in any of the groups, but the area under the curve was significantly higher in the RYGB than in the control group. CONCLUSIONS: Sustained weight loss maintenance seems to be associated with increased fasting levels of ghrelin and obestatin after RYGB surgery, but not after a lifestyle intervention, while maintaining ghrelin/obestatin ratio. Ghrelin is, therefore, unlikely to contribute to weight loss maintenance after RYGB, and other mechanisms are probably involved.
BACKGROUND: Appetite-regulating hormones seem to play an important role in weight loss after bariatric surgery. Less is known regarding long-term weight loss maintenance. The objective of the study was to evaluate ghrelin and obestatin levels following long-term weight loss achieved through bariatric surgery or a lifestyle intervention in morbidly obesepatients. METHODS: The study was cross-sectional in design carried out in a university research center setting. The participants were weight-stable morbidly obesepatients who had undergone, on average, 3 years ago, Roux-en-Y gastric bypass (RYGB) surgery (n=9) or a lifestyle weight loss intervention (n=8), and patients on a waiting list for bariatric surgery (control group; n=9). The main outcome measures were fasting/postprandial plasma levels of total ghrelin and obestatin and ghrelin/obestatin ratio. RESULTS: Fasting ghrelin and obestatin plasma levels were significantly elevated in the RYGB, but not in the lifestyle group, as compared with the control group. There was no statistical significant difference in fasting ghrelin/obestatin ratio among study groups. Ghrelin levels were suppressed after breakfast in all groups, with no significant differences in postprandial levels overtime between them. Obestatin levels did not change postprandially in any of the groups, but the area under the curve was significantly higher in the RYGB than in the control group. CONCLUSIONS:Sustained weight loss maintenance seems to be associated with increased fasting levels of ghrelin and obestatin after RYGB surgery, but not after a lifestyle intervention, while maintaining ghrelin/obestatin ratio. Ghrelin is, therefore, unlikely to contribute to weight loss maintenance after RYGB, and other mechanisms are probably involved.
Authors: May Faraj; Peter J Havel; Steve Phélis; David Blank; Allan D Sniderman; Katherine Cianflone Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: David E Cummings; David S Weigle; R Scott Frayo; Patricia A Breen; Marina K Ma; E Patchen Dellinger; Jonathan Q Purnell Journal: N Engl J Med Date: 2002-05-23 Impact factor: 91.245
Authors: H Ariyasu; K Takaya; T Tagami; Y Ogawa; K Hosoda; T Akamizu; M Suda; T Koh; K Natsui; S Toyooka; G Shirakami; T Usui; A Shimatsu; K Doi; H Hosoda; M Kojima; K Kangawa; K Nakao Journal: J Clin Endocrinol Metab Date: 2001-10 Impact factor: 5.958
Authors: H J Leidy; J K Gardner; B R Frye; M L Snook; M K Schuchert; E L Richard; N I Williams Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Bruno Geloneze; Marcos A Tambascia; Victor F Pilla; Sylka R Geloneze; Enrico M Repetto; José C Pareja Journal: Obes Surg Date: 2003-02 Impact factor: 4.129
Authors: C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad Journal: Diabetologia Date: 2012-04-27 Impact factor: 10.122
Authors: Carmine Finelli; Maria Carmela Padula; Giuseppe Martelli; Giovanni Tarantino Journal: World J Gastroenterol Date: 2014-11-28 Impact factor: 5.742
Authors: S H Jacobsen; S C Olesen; C Dirksen; N B Jørgensen; K N Bojsen-Møller; U Kielgast; D Worm; T Almdal; L S Naver; L E Hvolris; J F Rehfeld; B S Wulff; T R Clausen; D L Hansen; J J Holst; S Madsbad Journal: Obes Surg Date: 2012-07 Impact factor: 4.129
Authors: Jon F Davis; Andrea L Tracy; Jennifer D Schurdak; Irwin J Magrisso; Bernadette E Grayson; Randy J Seeley; Stephen C Benoit Journal: Obes Surg Date: 2013-07 Impact factor: 4.129
Authors: Hugo Mendieta Zerón; Ma Victoria Domínguez García; María Del Socorro Camarillo Romero; Miriam V Flores-Merino Journal: Int J Endocrinol Date: 2013-12-05 Impact factor: 3.257